Several independent studies using Ado receptor gene-targeted mouse models or selective Ado receptor inhibitors (45, 64–67) have established that Ado, mediated by A2A and/or A2B Ado receptors, inhibits the anti-tumor activity of CD8+ T cells, supporting metastasis and neoangiogenesis in cancerous tissues. This evidence concerns the gene CD8A and neoplasm.